Pharma News

Johnson & Johnson has handed in its New Drug Application for its multiple sclerosis (MS) hopeful as it hopes to get in on this blockbuster market.

Gilead has announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Epclusa (sofosbuvir 400mg/velpatasvir 100mg; sofosbu...

(Reuters) - U.

A phase 3 trial of Soligenix’s cutaneous T-cell lymphoma treatment has squeezed under the bar for statistical significance.

Months after the FDA pointed out manufacturing concerns at a Cipla plant in India—including workers using dirty disposable socks that may have caused contamination—the drugmaker said it was ready ...

A new study published in a BMJ journal has found that inadequate screening in heart failure has cost the NHS an avoidable £21.

Pfizer has revealed that its investigational Janus kinase 1 (JAK1) inhibitor, abrocitinib, has met its co-primary efficacy endpoints in a Phase III moderate to severe atopic dermatitis trial.

Oxford Biomedica has signed a Licence and Clinical Supply Agreement (LSA) with Bristol-Myers Squibb’s Juno Theraputics, granting the latter a non-exclusive license to the LentiVector platfor...

MSD has revealed new topline efficacy results from two ongoing pivotal Phase III trials, evaluating gefapixant (MK-7264) in refractory or unexplained chronic cough.

Biotech giant Regeneron said it aims to have doses of a potential drug for COVID-19 ready to start human clinical trials by early summer.

Geneva, 16 March 2020 – Bristol-Myers Squibb (BMS) has announced that the marketing authorisations for Daklinza® (daclatasvir) will be withdrawn or will be allowed to lapse in count...

Following government issued advice to avoid all non-essential travel and contact in the UK, various pharmaceutical companies are stepping up to offer vaccine candidates, funding and more.